Days af­ter FDA clears C3 drug, Apel­lis spot­lights ex-US PhI­II win among pa­tients who haven't tak­en Soliris

Through­out Apel­lis’ de­vel­op­ment pro­gram for pegc­eta­coplan — es­pe­cial­ly lead­ing up to its ap­proval days ago — CEO Cedric Fran­cois has of­ten billed its C3 in­hibitor as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER